In February, 2023 Imara merged with Enliven therapeutics (ELVN), with the resulting firm retaining Enliven’s name and development pipeline. Enliven is a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors to help patients with cancer live not only longer, but better.
View Top Employees from Imara Inc.Website | https://www.enliventherapeutics.com/ |
Revenue | $4 million |
Funding | $94 million |
Employees | 13 (9 on RocketReach) |
Founded | 2016 |
Phone | (617) 206-2020 |
Technologies |
JavaScript,
HTML,
PHP
+30 more
(view full list)
|
Industry | Biotechnology Research, Drug Manufacturing & Research, Collaboration, Pharmaceuticals, Genetics, Healthcare, Biotechnology, Health Care, Therapeutics |
Competitors | Agios Pharmaceuticals, Geron Corporation, Global Blood Therapeutics, Inc., GlycoMimetics, Supernus Pharmaceuticals, Inc. |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 325 Companies, NAICS Code 32 Companies |
Looking for a particular Imara Inc. employee's phone or email?
The Imara Inc. annual revenue was $4 million in 2024.
Wendy Kwan is the Director of Finance and Controller of Imara Inc..
9 people are employed at Imara Inc..
Imara Inc. is based in Boston, Massachusetts.
The NAICS codes for Imara Inc. are [32541, 3254, 325, 32].
The SIC codes for Imara Inc. are [28, 283].